nodes	percent_of_prediction	percent_of_DWPC	metapath
Lapatinib—breast cancer—bone cancer	0.555	1	CtDrD
Lapatinib—EGFR—bone cancer	0.248	0.732	CbGaD
Lapatinib—CYP3A4—bone cancer	0.0904	0.268	CbGaD
Lapatinib—Left ventricular ejection fraction decreased—Epirubicin—bone cancer	0.00276	0.0576	CcSEcCtD
Lapatinib—Left ventricular ejection fraction decreased—Doxorubicin—bone cancer	0.00256	0.0533	CcSEcCtD
Lapatinib—Metastatic neoplasm—Cisplatin—bone cancer	0.00234	0.0487	CcSEcCtD
Lapatinib—Metastatic disease—Epirubicin—bone cancer	0.002	0.0416	CcSEcCtD
Lapatinib—Gefitinib—CHEK2—bone cancer	0.00185	0.647	CrCbGaD
Lapatinib—Metastatic disease—Doxorubicin—bone cancer	0.00185	0.0385	CcSEcCtD
Lapatinib—Paronychia—Methotrexate—bone cancer	0.00142	0.0296	CcSEcCtD
Lapatinib—Ejection fraction decreased—Epirubicin—bone cancer	0.0014	0.0292	CcSEcCtD
Lapatinib—Ejection fraction decreased—Doxorubicin—bone cancer	0.0013	0.0271	CcSEcCtD
Lapatinib—Metastatic neoplasm—Epirubicin—bone cancer	0.0012	0.025	CcSEcCtD
Lapatinib—Metastatic neoplasm—Doxorubicin—bone cancer	0.00111	0.0232	CcSEcCtD
Lapatinib—Cardiotoxicity—Epirubicin—bone cancer	0.000977	0.0204	CcSEcCtD
Lapatinib—Cardiotoxicity—Doxorubicin—bone cancer	0.000904	0.0188	CcSEcCtD
Lapatinib—ERBB2—Doxorubicin—Epirubicin—bone cancer	0.000818	0.519	CbGdCrCtD
Lapatinib—Peripheral sensory neuropathy—Epirubicin—bone cancer	0.000805	0.0168	CcSEcCtD
Lapatinib—ERBB2—Epirubicin—Doxorubicin—bone cancer	0.000757	0.481	CbGdCrCtD
Lapatinib—Peripheral sensory neuropathy—Doxorubicin—bone cancer	0.000745	0.0155	CcSEcCtD
Lapatinib—Gefitinib—EGFR—bone cancer	0.000741	0.259	CrCbGaD
Lapatinib—Hepatotoxicity—Cisplatin—bone cancer	0.00058	0.0121	CcSEcCtD
Lapatinib—Infection—Carboplatin—bone cancer	0.000542	0.0113	CcSEcCtD
Lapatinib—Mucosal inflammation—Methotrexate—bone cancer	0.000444	0.00926	CcSEcCtD
Lapatinib—Mucosal inflammation—Epirubicin—bone cancer	0.000416	0.00867	CcSEcCtD
Lapatinib—Mucosal inflammation—Doxorubicin—bone cancer	0.000385	0.00802	CcSEcCtD
Lapatinib—Nail disorder—Methotrexate—bone cancer	0.000379	0.00791	CcSEcCtD
Lapatinib—Nail disorder—Epirubicin—bone cancer	0.000355	0.0074	CcSEcCtD
Lapatinib—Renal failure acute—Cisplatin—bone cancer	0.000352	0.00735	CcSEcCtD
Lapatinib—Interstitial lung disease—Methotrexate—bone cancer	0.000348	0.00725	CcSEcCtD
Lapatinib—Nail disorder—Doxorubicin—bone cancer	0.000328	0.00685	CcSEcCtD
Lapatinib—Hepatotoxicity—Methotrexate—bone cancer	0.000319	0.00664	CcSEcCtD
Lapatinib—Dehydration—Cisplatin—bone cancer	0.000303	0.00631	CcSEcCtD
Lapatinib—Blood disorder—Epirubicin—bone cancer	0.000276	0.00575	CcSEcCtD
Lapatinib—Gefitinib—CYP3A4—bone cancer	0.000271	0.0944	CrCbGaD
Lapatinib—Hyperbilirubinaemia—Methotrexate—bone cancer	0.00027	0.00564	CcSEcCtD
Lapatinib—Neoplasm malignant—Epirubicin—bone cancer	0.00027	0.00562	CcSEcCtD
Lapatinib—Blood disorder—Doxorubicin—bone cancer	0.000255	0.00532	CcSEcCtD
Lapatinib—Hyperbilirubinaemia—Epirubicin—bone cancer	0.000253	0.00528	CcSEcCtD
Lapatinib—Neoplasm malignant—Doxorubicin—bone cancer	0.000249	0.0052	CcSEcCtD
Lapatinib—Neuropathy peripheral—Cisplatin—bone cancer	0.000246	0.00512	CcSEcCtD
Lapatinib—Stomatitis—Cisplatin—bone cancer	0.000244	0.0051	CcSEcCtD
Lapatinib—Blood bilirubin increased—Epirubicin—bone cancer	0.000243	0.00507	CcSEcCtD
Lapatinib—Hepatobiliary disease—Cisplatin—bone cancer	0.000237	0.00494	CcSEcCtD
Lapatinib—Hyperbilirubinaemia—Doxorubicin—bone cancer	0.000234	0.00488	CcSEcCtD
Lapatinib—Blood bilirubin increased—Doxorubicin—bone cancer	0.000225	0.00469	CcSEcCtD
Lapatinib—Connective tissue disorder—Cisplatin—bone cancer	0.000221	0.00461	CcSEcCtD
Lapatinib—Cardiac disorder—Cisplatin—bone cancer	0.000209	0.00436	CcSEcCtD
Lapatinib—Immune system disorder—Cisplatin—bone cancer	0.000203	0.00424	CcSEcCtD
Lapatinib—Mediastinal disorder—Cisplatin—bone cancer	0.000203	0.00423	CcSEcCtD
Lapatinib—Alopecia—Cisplatin—bone cancer	0.000199	0.00415	CcSEcCtD
Lapatinib—Malnutrition—Cisplatin—bone cancer	0.000196	0.00409	CcSEcCtD
Lapatinib—Renal failure acute—Methotrexate—bone cancer	0.000193	0.00403	CcSEcCtD
Lapatinib—Anaemia—Cisplatin—bone cancer	0.000181	0.00378	CcSEcCtD
Lapatinib—Renal failure acute—Epirubicin—bone cancer	0.000181	0.00377	CcSEcCtD
Lapatinib—Hot flush—Epirubicin—bone cancer	0.000179	0.00372	CcSEcCtD
Lapatinib—Menopausal symptoms—Epirubicin—bone cancer	0.000177	0.00369	CcSEcCtD
Lapatinib—Leukopenia—Cisplatin—bone cancer	0.000175	0.00366	CcSEcCtD
Lapatinib—Cardiac failure—Epirubicin—bone cancer	0.000171	0.00357	CcSEcCtD
Lapatinib—Renal failure acute—Doxorubicin—bone cancer	0.000167	0.00349	CcSEcCtD
Lapatinib—Pain in extremity—Epirubicin—bone cancer	0.000167	0.00348	CcSEcCtD
Lapatinib—Myalgia—Cisplatin—bone cancer	0.000167	0.00348	CcSEcCtD
Lapatinib—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—bone cancer	0.000166	0.00345	CcSEcCtD
Lapatinib—Hot flush—Doxorubicin—bone cancer	0.000165	0.00345	CcSEcCtD
Lapatinib—Menopausal symptoms—Doxorubicin—bone cancer	0.000164	0.00342	CcSEcCtD
Lapatinib—Anaphylactic shock—Cisplatin—bone cancer	0.00016	0.00333	CcSEcCtD
Lapatinib—Infection—Cisplatin—bone cancer	0.000159	0.00331	CcSEcCtD
Lapatinib—Cardiac failure—Doxorubicin—bone cancer	0.000158	0.0033	CcSEcCtD
Lapatinib—Nervous system disorder—Cisplatin—bone cancer	0.000157	0.00327	CcSEcCtD
Lapatinib—Dehydration—Epirubicin—bone cancer	0.000155	0.00324	CcSEcCtD
Lapatinib—Skin disorder—Cisplatin—bone cancer	0.000155	0.00324	CcSEcCtD
Lapatinib—Pain in extremity—Doxorubicin—bone cancer	0.000155	0.00322	CcSEcCtD
Lapatinib—Dry skin—Epirubicin—bone cancer	0.000153	0.00319	CcSEcCtD
Lapatinib—Anorexia—Cisplatin—bone cancer	0.000152	0.00318	CcSEcCtD
Lapatinib—Alanine aminotransferase increased—Epirubicin—bone cancer	0.000147	0.00307	CcSEcCtD
Lapatinib—Musculoskeletal discomfort—Cisplatin—bone cancer	0.000146	0.00304	CcSEcCtD
Lapatinib—Neutropenia—Methotrexate—bone cancer	0.000144	0.00301	CcSEcCtD
Lapatinib—Dehydration—Doxorubicin—bone cancer	0.000144	0.003	CcSEcCtD
Lapatinib—Dyspnoea—Cisplatin—bone cancer	0.000143	0.00297	CcSEcCtD
Lapatinib—Dry skin—Doxorubicin—bone cancer	0.000142	0.00295	CcSEcCtD
Lapatinib—Decreased appetite—Cisplatin—bone cancer	0.000139	0.0029	CcSEcCtD
Lapatinib—Pneumonia—Methotrexate—bone cancer	0.000138	0.00289	CcSEcCtD
Lapatinib—Gastrointestinal disorder—Cisplatin—bone cancer	0.000138	0.00288	CcSEcCtD
Lapatinib—Infestation NOS—Methotrexate—bone cancer	0.000138	0.00287	CcSEcCtD
Lapatinib—Infestation—Methotrexate—bone cancer	0.000138	0.00287	CcSEcCtD
Lapatinib—Alanine aminotransferase increased—Doxorubicin—bone cancer	0.000136	0.00284	CcSEcCtD
Lapatinib—Neutropenia—Epirubicin—bone cancer	0.000135	0.00282	CcSEcCtD
Lapatinib—Stomatitis—Methotrexate—bone cancer	0.000134	0.0028	CcSEcCtD
Lapatinib—Hepatobiliary disease—Methotrexate—bone cancer	0.00013	0.00271	CcSEcCtD
Lapatinib—Epistaxis—Methotrexate—bone cancer	0.00013	0.00271	CcSEcCtD
Lapatinib—Pneumonia—Epirubicin—bone cancer	0.00013	0.0027	CcSEcCtD
Lapatinib—Infestation NOS—Epirubicin—bone cancer	0.000129	0.00268	CcSEcCtD
Lapatinib—Infestation—Epirubicin—bone cancer	0.000129	0.00268	CcSEcCtD
Lapatinib—Neuropathy peripheral—Epirubicin—bone cancer	0.000126	0.00263	CcSEcCtD
Lapatinib—Stomatitis—Epirubicin—bone cancer	0.000126	0.00262	CcSEcCtD
Lapatinib—Neutropenia—Doxorubicin—bone cancer	0.000125	0.00261	CcSEcCtD
Lapatinib—Hepatobiliary disease—Epirubicin—bone cancer	0.000122	0.00254	CcSEcCtD
Lapatinib—Epistaxis—Epirubicin—bone cancer	0.000121	0.00253	CcSEcCtD
Lapatinib—Pneumonia—Doxorubicin—bone cancer	0.00012	0.0025	CcSEcCtD
Lapatinib—Infestation NOS—Doxorubicin—bone cancer	0.000119	0.00248	CcSEcCtD
Lapatinib—Infestation—Doxorubicin—bone cancer	0.000119	0.00248	CcSEcCtD
Lapatinib—Hypersensitivity—Cisplatin—bone cancer	0.000118	0.00246	CcSEcCtD
Lapatinib—Neuropathy peripheral—Doxorubicin—bone cancer	0.000117	0.00244	CcSEcCtD
Lapatinib—Stomatitis—Doxorubicin—bone cancer	0.000116	0.00242	CcSEcCtD
Lapatinib—Asthenia—Cisplatin—bone cancer	0.000115	0.00239	CcSEcCtD
Lapatinib—Cardiac disorder—Methotrexate—bone cancer	0.000115	0.00239	CcSEcCtD
Lapatinib—Connective tissue disorder—Epirubicin—bone cancer	0.000114	0.00237	CcSEcCtD
Lapatinib—Hepatobiliary disease—Doxorubicin—bone cancer	0.000113	0.00235	CcSEcCtD
Lapatinib—Epistaxis—Doxorubicin—bone cancer	0.000112	0.00234	CcSEcCtD
Lapatinib—Angiopathy—Methotrexate—bone cancer	0.000112	0.00234	CcSEcCtD
Lapatinib—Immune system disorder—Methotrexate—bone cancer	0.000112	0.00233	CcSEcCtD
Lapatinib—Mediastinal disorder—Methotrexate—bone cancer	0.000111	0.00232	CcSEcCtD
Lapatinib—Diarrhoea—Cisplatin—bone cancer	0.000109	0.00228	CcSEcCtD
Lapatinib—Alopecia—Methotrexate—bone cancer	0.000109	0.00228	CcSEcCtD
Lapatinib—Mental disorder—Methotrexate—bone cancer	0.000108	0.00226	CcSEcCtD
Lapatinib—Malnutrition—Methotrexate—bone cancer	0.000108	0.00224	CcSEcCtD
Lapatinib—Cardiac disorder—Epirubicin—bone cancer	0.000107	0.00224	CcSEcCtD
Lapatinib—Connective tissue disorder—Doxorubicin—bone cancer	0.000105	0.00219	CcSEcCtD
Lapatinib—Angiopathy—Epirubicin—bone cancer	0.000105	0.00219	CcSEcCtD
Lapatinib—Immune system disorder—Epirubicin—bone cancer	0.000104	0.00218	CcSEcCtD
Lapatinib—Mediastinal disorder—Epirubicin—bone cancer	0.000104	0.00217	CcSEcCtD
Lapatinib—Back pain—Methotrexate—bone cancer	0.000104	0.00217	CcSEcCtD
Lapatinib—Alopecia—Epirubicin—bone cancer	0.000102	0.00213	CcSEcCtD
Lapatinib—Vomiting—Cisplatin—bone cancer	0.000102	0.00212	CcSEcCtD
Lapatinib—Mental disorder—Epirubicin—bone cancer	0.000101	0.00211	CcSEcCtD
Lapatinib—Rash—Cisplatin—bone cancer	0.000101	0.0021	CcSEcCtD
Lapatinib—Dermatitis—Cisplatin—bone cancer	0.000101	0.0021	CcSEcCtD
Lapatinib—Malnutrition—Epirubicin—bone cancer	0.000101	0.0021	CcSEcCtD
Lapatinib—Anaemia—Methotrexate—bone cancer	9.94e-05	0.00207	CcSEcCtD
Lapatinib—Cardiac disorder—Doxorubicin—bone cancer	9.93e-05	0.00207	CcSEcCtD
Lapatinib—Back pain—Epirubicin—bone cancer	9.73e-05	0.00203	CcSEcCtD
Lapatinib—Angiopathy—Doxorubicin—bone cancer	9.7e-05	0.00202	CcSEcCtD
Lapatinib—Immune system disorder—Doxorubicin—bone cancer	9.66e-05	0.00201	CcSEcCtD
Lapatinib—Mediastinal disorder—Doxorubicin—bone cancer	9.64e-05	0.00201	CcSEcCtD
Lapatinib—Leukopenia—Methotrexate—bone cancer	9.62e-05	0.00201	CcSEcCtD
Lapatinib—Nausea—Cisplatin—bone cancer	9.5e-05	0.00198	CcSEcCtD
Lapatinib—Alopecia—Doxorubicin—bone cancer	9.45e-05	0.00197	CcSEcCtD
Lapatinib—Cough—Methotrexate—bone cancer	9.38e-05	0.00196	CcSEcCtD
Lapatinib—Mental disorder—Doxorubicin—bone cancer	9.37e-05	0.00195	CcSEcCtD
Lapatinib—Malnutrition—Doxorubicin—bone cancer	9.31e-05	0.00194	CcSEcCtD
Lapatinib—Anaemia—Epirubicin—bone cancer	9.3e-05	0.00194	CcSEcCtD
Lapatinib—Myalgia—Methotrexate—bone cancer	9.15e-05	0.00191	CcSEcCtD
Lapatinib—Arthralgia—Methotrexate—bone cancer	9.15e-05	0.00191	CcSEcCtD
Lapatinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	9.09e-05	0.0019	CcSEcCtD
Lapatinib—Leukopenia—Epirubicin—bone cancer	9.01e-05	0.00188	CcSEcCtD
Lapatinib—Back pain—Doxorubicin—bone cancer	9.01e-05	0.00188	CcSEcCtD
Lapatinib—Palpitations—Epirubicin—bone cancer	8.89e-05	0.00185	CcSEcCtD
Lapatinib—Cough—Epirubicin—bone cancer	8.78e-05	0.00183	CcSEcCtD
Lapatinib—Anaphylactic shock—Methotrexate—bone cancer	8.78e-05	0.00183	CcSEcCtD
Lapatinib—Infection—Methotrexate—bone cancer	8.72e-05	0.00182	CcSEcCtD
Lapatinib—Nervous system disorder—Methotrexate—bone cancer	8.61e-05	0.00179	CcSEcCtD
Lapatinib—Anaemia—Doxorubicin—bone cancer	8.61e-05	0.00179	CcSEcCtD
Lapatinib—Myalgia—Epirubicin—bone cancer	8.57e-05	0.00179	CcSEcCtD
Lapatinib—Arthralgia—Epirubicin—bone cancer	8.57e-05	0.00179	CcSEcCtD
Lapatinib—Skin disorder—Methotrexate—bone cancer	8.52e-05	0.00178	CcSEcCtD
Lapatinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	8.51e-05	0.00177	CcSEcCtD
Lapatinib—Anorexia—Methotrexate—bone cancer	8.36e-05	0.00174	CcSEcCtD
Lapatinib—Leukopenia—Doxorubicin—bone cancer	8.33e-05	0.00174	CcSEcCtD
Lapatinib—Palpitations—Doxorubicin—bone cancer	8.23e-05	0.00172	CcSEcCtD
Lapatinib—Anaphylactic shock—Epirubicin—bone cancer	8.21e-05	0.00171	CcSEcCtD
Lapatinib—Infection—Epirubicin—bone cancer	8.16e-05	0.0017	CcSEcCtD
Lapatinib—Cough—Doxorubicin—bone cancer	8.12e-05	0.00169	CcSEcCtD
Lapatinib—Nervous system disorder—Epirubicin—bone cancer	8.05e-05	0.00168	CcSEcCtD
Lapatinib—Musculoskeletal discomfort—Methotrexate—bone cancer	8e-05	0.00167	CcSEcCtD
Lapatinib—Skin disorder—Epirubicin—bone cancer	7.98e-05	0.00166	CcSEcCtD
Lapatinib—Insomnia—Methotrexate—bone cancer	7.94e-05	0.00165	CcSEcCtD
Lapatinib—Arthralgia—Doxorubicin—bone cancer	7.93e-05	0.00165	CcSEcCtD
Lapatinib—Myalgia—Doxorubicin—bone cancer	7.93e-05	0.00165	CcSEcCtD
Lapatinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	7.87e-05	0.00164	CcSEcCtD
Lapatinib—Anorexia—Epirubicin—bone cancer	7.83e-05	0.00163	CcSEcCtD
Lapatinib—Dyspnoea—Methotrexate—bone cancer	7.82e-05	0.00163	CcSEcCtD
Lapatinib—Dyspepsia—Methotrexate—bone cancer	7.72e-05	0.00161	CcSEcCtD
Lapatinib—Decreased appetite—Methotrexate—bone cancer	7.63e-05	0.00159	CcSEcCtD
Lapatinib—Anaphylactic shock—Doxorubicin—bone cancer	7.6e-05	0.00158	CcSEcCtD
Lapatinib—Gastrointestinal disorder—Methotrexate—bone cancer	7.58e-05	0.00158	CcSEcCtD
Lapatinib—Fatigue—Methotrexate—bone cancer	7.57e-05	0.00158	CcSEcCtD
Lapatinib—Infection—Doxorubicin—bone cancer	7.55e-05	0.00157	CcSEcCtD
Lapatinib—Musculoskeletal discomfort—Epirubicin—bone cancer	7.48e-05	0.00156	CcSEcCtD
Lapatinib—Nervous system disorder—Doxorubicin—bone cancer	7.45e-05	0.00155	CcSEcCtD
Lapatinib—Insomnia—Epirubicin—bone cancer	7.43e-05	0.00155	CcSEcCtD
Lapatinib—Skin disorder—Doxorubicin—bone cancer	7.38e-05	0.00154	CcSEcCtD
Lapatinib—Dyspnoea—Epirubicin—bone cancer	7.32e-05	0.00153	CcSEcCtD
Lapatinib—Anorexia—Doxorubicin—bone cancer	7.24e-05	0.00151	CcSEcCtD
Lapatinib—Dyspepsia—Epirubicin—bone cancer	7.23e-05	0.00151	CcSEcCtD
Lapatinib—Gastrointestinal pain—Methotrexate—bone cancer	7.18e-05	0.0015	CcSEcCtD
Lapatinib—Decreased appetite—Epirubicin—bone cancer	7.14e-05	0.00149	CcSEcCtD
Lapatinib—Gastrointestinal disorder—Epirubicin—bone cancer	7.09e-05	0.00148	CcSEcCtD
Lapatinib—Fatigue—Epirubicin—bone cancer	7.08e-05	0.00148	CcSEcCtD
Lapatinib—Constipation—Epirubicin—bone cancer	7.02e-05	0.00146	CcSEcCtD
Lapatinib—Abdominal pain—Methotrexate—bone cancer	6.94e-05	0.00145	CcSEcCtD
Lapatinib—Musculoskeletal discomfort—Doxorubicin—bone cancer	6.92e-05	0.00144	CcSEcCtD
Lapatinib—Insomnia—Doxorubicin—bone cancer	6.87e-05	0.00143	CcSEcCtD
Lapatinib—Dyspnoea—Doxorubicin—bone cancer	6.77e-05	0.00141	CcSEcCtD
Lapatinib—Gastrointestinal pain—Epirubicin—bone cancer	6.72e-05	0.0014	CcSEcCtD
Lapatinib—Dyspepsia—Doxorubicin—bone cancer	6.69e-05	0.00139	CcSEcCtD
Lapatinib—Decreased appetite—Doxorubicin—bone cancer	6.61e-05	0.00138	CcSEcCtD
Lapatinib—Gastrointestinal disorder—Doxorubicin—bone cancer	6.56e-05	0.00137	CcSEcCtD
Lapatinib—Fatigue—Doxorubicin—bone cancer	6.55e-05	0.00137	CcSEcCtD
Lapatinib—Constipation—Doxorubicin—bone cancer	6.5e-05	0.00135	CcSEcCtD
Lapatinib—Abdominal pain—Epirubicin—bone cancer	6.49e-05	0.00135	CcSEcCtD
Lapatinib—Hypersensitivity—Methotrexate—bone cancer	6.47e-05	0.00135	CcSEcCtD
Lapatinib—Asthenia—Methotrexate—bone cancer	6.3e-05	0.00131	CcSEcCtD
Lapatinib—Gastrointestinal pain—Doxorubicin—bone cancer	6.21e-05	0.0013	CcSEcCtD
Lapatinib—Pruritus—Methotrexate—bone cancer	6.21e-05	0.00129	CcSEcCtD
Lapatinib—Hypersensitivity—Epirubicin—bone cancer	6.05e-05	0.00126	CcSEcCtD
Lapatinib—Abdominal pain—Doxorubicin—bone cancer	6.01e-05	0.00125	CcSEcCtD
Lapatinib—Diarrhoea—Methotrexate—bone cancer	6e-05	0.00125	CcSEcCtD
Lapatinib—Asthenia—Epirubicin—bone cancer	5.89e-05	0.00123	CcSEcCtD
Lapatinib—Pruritus—Epirubicin—bone cancer	5.81e-05	0.00121	CcSEcCtD
Lapatinib—Diarrhoea—Epirubicin—bone cancer	5.62e-05	0.00117	CcSEcCtD
Lapatinib—Hypersensitivity—Doxorubicin—bone cancer	5.6e-05	0.00117	CcSEcCtD
Lapatinib—Vomiting—Methotrexate—bone cancer	5.58e-05	0.00116	CcSEcCtD
Lapatinib—Rash—Methotrexate—bone cancer	5.53e-05	0.00115	CcSEcCtD
Lapatinib—Dermatitis—Methotrexate—bone cancer	5.53e-05	0.00115	CcSEcCtD
Lapatinib—Headache—Methotrexate—bone cancer	5.5e-05	0.00115	CcSEcCtD
Lapatinib—Asthenia—Doxorubicin—bone cancer	5.45e-05	0.00114	CcSEcCtD
Lapatinib—Pruritus—Doxorubicin—bone cancer	5.38e-05	0.00112	CcSEcCtD
Lapatinib—Vomiting—Epirubicin—bone cancer	5.22e-05	0.00109	CcSEcCtD
Lapatinib—Nausea—Methotrexate—bone cancer	5.21e-05	0.00109	CcSEcCtD
Lapatinib—Diarrhoea—Doxorubicin—bone cancer	5.2e-05	0.00108	CcSEcCtD
Lapatinib—Rash—Epirubicin—bone cancer	5.18e-05	0.00108	CcSEcCtD
Lapatinib—Dermatitis—Epirubicin—bone cancer	5.17e-05	0.00108	CcSEcCtD
Lapatinib—Headache—Epirubicin—bone cancer	5.14e-05	0.00107	CcSEcCtD
Lapatinib—Nausea—Epirubicin—bone cancer	4.88e-05	0.00102	CcSEcCtD
Lapatinib—Vomiting—Doxorubicin—bone cancer	4.83e-05	0.00101	CcSEcCtD
Lapatinib—Rash—Doxorubicin—bone cancer	4.79e-05	0.000999	CcSEcCtD
Lapatinib—Dermatitis—Doxorubicin—bone cancer	4.79e-05	0.000998	CcSEcCtD
Lapatinib—Headache—Doxorubicin—bone cancer	4.76e-05	0.000993	CcSEcCtD
Lapatinib—Nausea—Doxorubicin—bone cancer	4.51e-05	0.000941	CcSEcCtD
Lapatinib—EGFR—DAP12 interactions—KIT—bone cancer	3.73e-05	0.000682	CbGpPWpGaD
Lapatinib—EGFR—Signaling by FGFR in disease—KIT—bone cancer	3.73e-05	0.000682	CbGpPWpGaD
Lapatinib—EGFR—Fc epsilon receptor (FCERI) signaling—KIT—bone cancer	3.73e-05	0.000682	CbGpPWpGaD
Lapatinib—EGFR—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	3.72e-05	0.000682	CbGpPWpGaD
Lapatinib—EGFR—Signaling by EGFR—KIT—bone cancer	3.69e-05	0.000676	CbGpPWpGaD
Lapatinib—CYP3A5—Metapathway biotransformation—GSTP1—bone cancer	3.69e-05	0.000675	CbGpPWpGaD
Lapatinib—ERBB2—NGF signalling via TRKA from the plasma membrane—EGFR—bone cancer	3.67e-05	0.000673	CbGpPWpGaD
Lapatinib—EGFR—Rac1/Pak1/p38/MMP-2 pathway—TP53—bone cancer	3.66e-05	0.000671	CbGpPWpGaD
Lapatinib—EGFR—Signaling by EGFR in Cancer—KIT—bone cancer	3.66e-05	0.00067	CbGpPWpGaD
Lapatinib—ABCB1—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	3.66e-05	0.000669	CbGpPWpGaD
Lapatinib—TAP1—Immune System—MDM2—bone cancer	3.66e-05	0.000669	CbGpPWpGaD
Lapatinib—EGFR—MAPK Signaling Pathway—BRAF—bone cancer	3.65e-05	0.000669	CbGpPWpGaD
Lapatinib—EGFR—Signaling by PDGF—KIT—bone cancer	3.64e-05	0.000667	CbGpPWpGaD
Lapatinib—ERBB4—NGF signalling via TRKA from the plasma membrane—EGFR—bone cancer	3.62e-05	0.000663	CbGpPWpGaD
Lapatinib—ERBB2—Developmental Biology—MET—bone cancer	3.6e-05	0.000659	CbGpPWpGaD
Lapatinib—ERBB2—Developmental Biology—CDK4—bone cancer	3.6e-05	0.000659	CbGpPWpGaD
Lapatinib—EGFR—Direct p53 effectors—MDM2—bone cancer	3.54e-05	0.000648	CbGpPWpGaD
Lapatinib—EGFR—Signaling by SCF-KIT—MDM2—bone cancer	3.52e-05	0.000644	CbGpPWpGaD
Lapatinib—ERBB2—Disease—ENO2—bone cancer	3.51e-05	0.000643	CbGpPWpGaD
Lapatinib—EGFR—Signaling by FGFR in disease—BRAF—bone cancer	3.5e-05	0.000641	CbGpPWpGaD
Lapatinib—ERBB4—Disease—ENO2—bone cancer	3.46e-05	0.000633	CbGpPWpGaD
Lapatinib—EGFR—B Cell Activation—KIT—bone cancer	3.45e-05	0.000631	CbGpPWpGaD
Lapatinib—EGFR—Spinal Cord Injury—MMP9—bone cancer	3.43e-05	0.000628	CbGpPWpGaD
Lapatinib—CYP2C19—Biological oxidations—CYP3A4—bone cancer	3.38e-05	0.000618	CbGpPWpGaD
Lapatinib—EGFR—Downstream signaling of activated FGFR—MDM2—bone cancer	3.37e-05	0.000617	CbGpPWpGaD
Lapatinib—EGFR—Integrated Breast Cancer Pathway—MDM2—bone cancer	3.33e-05	0.00061	CbGpPWpGaD
Lapatinib—CYP2C19—Metapathway biotransformation—CYP3A4—bone cancer	3.33e-05	0.00061	CbGpPWpGaD
Lapatinib—ABCB1—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	3.33e-05	0.00061	CbGpPWpGaD
Lapatinib—EGFR—Signaling by ERBB4—MDM2—bone cancer	3.31e-05	0.000607	CbGpPWpGaD
Lapatinib—EGFR—Focal Adhesion—BRAF—bone cancer	3.31e-05	0.000606	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—GRM1—bone cancer	3.31e-05	0.000606	CbGpPWpGaD
Lapatinib—EGFR—NGF signalling via TRKA from the plasma membrane—KIT—bone cancer	3.3e-05	0.000604	CbGpPWpGaD
Lapatinib—ERBB2—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	3.28e-05	0.0006	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—GRM1—bone cancer	3.26e-05	0.000596	CbGpPWpGaD
Lapatinib—ERBB2—Disease—DHFR—bone cancer	3.26e-05	0.000596	CbGpPWpGaD
Lapatinib—CYP2C8—Biological oxidations—GSTP1—bone cancer	3.24e-05	0.000593	CbGpPWpGaD
Lapatinib—ERBB4—Disease—DHFR—bone cancer	3.21e-05	0.000587	CbGpPWpGaD
Lapatinib—CYP2C8—Metapathway biotransformation—GSTP1—bone cancer	3.19e-05	0.000584	CbGpPWpGaD
Lapatinib—TAP1—Immune System—JUN—bone cancer	3.18e-05	0.000582	CbGpPWpGaD
Lapatinib—EGFR—Downstream signal transduction—MDM2—bone cancer	3.17e-05	0.00058	CbGpPWpGaD
Lapatinib—ERBB2—Axon guidance—MMP9—bone cancer	3.16e-05	0.000579	CbGpPWpGaD
Lapatinib—EGFR—Signaling by FGFR—MDM2—bone cancer	3.15e-05	0.000577	CbGpPWpGaD
Lapatinib—EGFR—Signaling by ERBB2—MDM2—bone cancer	3.13e-05	0.000574	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—GRM4—bone cancer	3.12e-05	0.000572	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—RGS1—bone cancer	3.12e-05	0.000572	CbGpPWpGaD
Lapatinib—EGFR—DAP12 signaling—MDM2—bone cancer	3.12e-05	0.000571	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways in Glioblastoma—TP53—bone cancer	3.12e-05	0.00057	CbGpPWpGaD
Lapatinib—EGFR—NGF signalling via TRKA from the plasma membrane—BRAF—bone cancer	3.1e-05	0.000568	CbGpPWpGaD
Lapatinib—EGFR—Direct p53 effectors—JUN—bone cancer	3.08e-05	0.000563	CbGpPWpGaD
Lapatinib—EGFR—Downstream signaling events of B Cell Receptor (BCR)—MDM2—bone cancer	3.07e-05	0.000563	CbGpPWpGaD
Lapatinib—ERBB2—Immune System—ATF1—bone cancer	3.06e-05	0.000561	CbGpPWpGaD
Lapatinib—ABCB1—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	3.03e-05	0.000555	CbGpPWpGaD
Lapatinib—ERBB4—Immune System—ATF1—bone cancer	3.02e-05	0.000553	CbGpPWpGaD
Lapatinib—ERBB2—Developmental Biology—MMP2—bone cancer	3e-05	0.00055	CbGpPWpGaD
Lapatinib—ERBB2—Innate Immune System—KIT—bone cancer	2.99e-05	0.000548	CbGpPWpGaD
Lapatinib—ABCB1—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	2.99e-05	0.000548	CbGpPWpGaD
Lapatinib—ERBB2—Immune System—IL3—bone cancer	2.99e-05	0.000547	CbGpPWpGaD
Lapatinib—EGFR—Signaling by SCF-KIT—MMP9—bone cancer	2.98e-05	0.000545	CbGpPWpGaD
Lapatinib—ERBB4—Innate Immune System—KIT—bone cancer	2.95e-05	0.00054	CbGpPWpGaD
Lapatinib—ERBB4—Immune System—IL3—bone cancer	2.94e-05	0.000539	CbGpPWpGaD
Lapatinib—EGFR—DAP12 interactions—MDM2—bone cancer	2.93e-05	0.000537	CbGpPWpGaD
Lapatinib—EGFR—Fc epsilon receptor (FCERI) signaling—MDM2—bone cancer	2.93e-05	0.000537	CbGpPWpGaD
Lapatinib—EGFR—Signaling by FGFR in disease—MDM2—bone cancer	2.93e-05	0.000537	CbGpPWpGaD
Lapatinib—EGFR—Signaling by EGFR—MDM2—bone cancer	2.91e-05	0.000532	CbGpPWpGaD
Lapatinib—EGFR—Integrated Breast Cancer Pathway—JUN—bone cancer	2.9e-05	0.00053	CbGpPWpGaD
Lapatinib—CYP2C19—Biological oxidations—GSTP1—bone cancer	2.89e-05	0.000529	CbGpPWpGaD
Lapatinib—EGFR—Signaling by EGFR in Cancer—MDM2—bone cancer	2.88e-05	0.000528	CbGpPWpGaD
Lapatinib—ERBB2—Adaptive Immune System—KIT—bone cancer	2.88e-05	0.000526	CbGpPWpGaD
Lapatinib—EGFR—Signaling by PDGF—MDM2—bone cancer	2.87e-05	0.000525	CbGpPWpGaD
Lapatinib—CYP2C19—Metapathway biotransformation—GSTP1—bone cancer	2.85e-05	0.000522	CbGpPWpGaD
Lapatinib—ABCB1—HIF-1-alpha transcription factor network—JUN—bone cancer	2.83e-05	0.000519	CbGpPWpGaD
Lapatinib—ERBB4—Adaptive Immune System—KIT—bone cancer	2.83e-05	0.000519	CbGpPWpGaD
Lapatinib—ERBB2—Signaling by NGF—EGFR—bone cancer	2.83e-05	0.000517	CbGpPWpGaD
Lapatinib—ERBB4—Signaling by NGF—EGFR—bone cancer	2.78e-05	0.00051	CbGpPWpGaD
Lapatinib—EGFR—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	2.76e-05	0.000506	CbGpPWpGaD
Lapatinib—EGFR—EGF/EGFR Signaling Pathway—JUN—bone cancer	2.74e-05	0.000501	CbGpPWpGaD
Lapatinib—EGFR—B Cell Activation—MDM2—bone cancer	2.72e-05	0.000497	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—GRM1—bone cancer	2.71e-05	0.000496	CbGpPWpGaD
Lapatinib—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	2.68e-05	0.000491	CbGpPWpGaD
Lapatinib—EGFR—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	2.66e-05	0.000487	CbGpPWpGaD
Lapatinib—EGFR—MAPK Signaling Pathway—JUN—bone cancer	2.66e-05	0.000487	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—NDUFA12—bone cancer	2.62e-05	0.00048	CbGpPWpGaD
Lapatinib—EGFR—NGF signalling via TRKA from the plasma membrane—MDM2—bone cancer	2.6e-05	0.000476	CbGpPWpGaD
Lapatinib—ERBB2—Axon guidance—EGFR—bone cancer	2.56e-05	0.000468	CbGpPWpGaD
Lapatinib—EGFR—Fc epsilon receptor (FCERI) signaling—JUN—bone cancer	2.55e-05	0.000467	CbGpPWpGaD
Lapatinib—EGFR—Innate Immune System—ATF1—bone cancer	2.54e-05	0.000466	CbGpPWpGaD
Lapatinib—EGFR—Signaling by NGF—KIT—bone cancer	2.54e-05	0.000465	CbGpPWpGaD
Lapatinib—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	2.53e-05	0.000464	CbGpPWpGaD
Lapatinib—ABCB1—Transmembrane transport of small molecules—TUBB4B—bone cancer	2.53e-05	0.000463	CbGpPWpGaD
Lapatinib—PIK3C2B—Metabolism—PTGS2—bone cancer	2.51e-05	0.00046	CbGpPWpGaD
Lapatinib—TAP1—Immune System—EGFR—bone cancer	2.5e-05	0.000457	CbGpPWpGaD
Lapatinib—EGFR—Axon guidance—MET—bone cancer	2.44e-05	0.000447	CbGpPWpGaD
Lapatinib—PI4KB—Metabolism—PTGS2—bone cancer	2.43e-05	0.000445	CbGpPWpGaD
Lapatinib—EGFR—Focal Adhesion—JUN—bone cancer	2.41e-05	0.000441	CbGpPWpGaD
Lapatinib—EGFR—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	2.4e-05	0.000439	CbGpPWpGaD
Lapatinib—EGFR—Signaling by NGF—BRAF—bone cancer	2.39e-05	0.000437	CbGpPWpGaD
Lapatinib—ERBB2—Disease—TGFBR2—bone cancer	2.36e-05	0.000432	CbGpPWpGaD
Lapatinib—ERBB2—Innate Immune System—MDM2—bone cancer	2.36e-05	0.000432	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—SMO—bone cancer	2.33e-05	0.000427	CbGpPWpGaD
Lapatinib—EGFR—Spinal Cord Injury—TP53—bone cancer	2.33e-05	0.000426	CbGpPWpGaD
Lapatinib—ERBB4—Disease—TGFBR2—bone cancer	2.32e-05	0.000426	CbGpPWpGaD
Lapatinib—ERBB4—Innate Immune System—MDM2—bone cancer	2.32e-05	0.000425	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—SMO—bone cancer	2.3e-05	0.00042	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—NDUFA12—bone cancer	2.27e-05	0.000415	CbGpPWpGaD
Lapatinib—ERBB2—Adaptive Immune System—MDM2—bone cancer	2.26e-05	0.000415	CbGpPWpGaD
Lapatinib—ERBB2—Developmental Biology—MMP9—bone cancer	2.26e-05	0.000413	CbGpPWpGaD
Lapatinib—ERBB4—Adaptive Immune System—MDM2—bone cancer	2.23e-05	0.000408	CbGpPWpGaD
Lapatinib—ABCB1—Transmembrane transport of small molecules—TUBB2A—bone cancer	2.18e-05	0.0004	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—NT5C3A—bone cancer	2.17e-05	0.000397	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—GNA11—bone cancer	2.13e-05	0.00039	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—GNA11—bone cancer	2.1e-05	0.000384	CbGpPWpGaD
Lapatinib—ERBB2—Innate Immune System—JUN—bone cancer	2.05e-05	0.000375	CbGpPWpGaD
Lapatinib—EGFR—Axon guidance—MMP2—bone cancer	2.04e-05	0.000373	CbGpPWpGaD
Lapatinib—EGFR—Direct p53 effectors—TP53—bone cancer	2.03e-05	0.000372	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—NDUFA12—bone cancer	2.02e-05	0.000371	CbGpPWpGaD
Lapatinib—ERBB4—Innate Immune System—JUN—bone cancer	2.02e-05	0.00037	CbGpPWpGaD
Lapatinib—EGFR—Signaling by NGF—MDM2—bone cancer	2e-05	0.000366	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—ATF1—bone cancer	1.98e-05	0.000363	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—NDUFA12—bone cancer	1.98e-05	0.000362	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—ATF1—bone cancer	1.95e-05	0.000357	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—IL3—bone cancer	1.93e-05	0.000354	CbGpPWpGaD
Lapatinib—EGFR—Integrated Breast Cancer Pathway—TP53—bone cancer	1.91e-05	0.00035	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—SMO—bone cancer	1.91e-05	0.000349	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—IL3—bone cancer	1.9e-05	0.000348	CbGpPWpGaD
Lapatinib—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	1.88e-05	0.000344	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—NT5C3A—bone cancer	1.88e-05	0.000344	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—RGS1—bone cancer	1.84e-05	0.000338	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—GRM4—bone cancer	1.84e-05	0.000338	CbGpPWpGaD
Lapatinib—ERBB2—Developmental Biology—EGFR—bone cancer	1.82e-05	0.000334	CbGpPWpGaD
Lapatinib—EGFR—MAPK Signaling Pathway—TP53—bone cancer	1.76e-05	0.000321	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—GNA11—bone cancer	1.74e-05	0.000319	CbGpPWpGaD
Lapatinib—ERBB2—Immune System—KIT—bone cancer	1.74e-05	0.000319	CbGpPWpGaD
Lapatinib—EGFR—Developmental Biology—CDK4—bone cancer	1.74e-05	0.000319	CbGpPWpGaD
Lapatinib—EGFR—Developmental Biology—MET—bone cancer	1.74e-05	0.000319	CbGpPWpGaD
Lapatinib—CYP3A4—Biological oxidations—GSTP1—bone cancer	1.74e-05	0.000318	CbGpPWpGaD
Lapatinib—ERBB4—Immune System—KIT—bone cancer	1.72e-05	0.000315	CbGpPWpGaD
Lapatinib—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	1.71e-05	0.000314	CbGpPWpGaD
Lapatinib—EGFR—Disease—ENO2—bone cancer	1.7e-05	0.000311	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—NT5C3A—bone cancer	1.68e-05	0.000307	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—TGFBR2—bone cancer	1.65e-05	0.000303	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—NT5C3A—bone cancer	1.64e-05	0.0003	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—TGFBR2—bone cancer	1.63e-05	0.000298	CbGpPWpGaD
Lapatinib—ERBB2—Innate Immune System—EGFR—bone cancer	1.61e-05	0.000295	CbGpPWpGaD
Lapatinib—ERBB2—Disease—KIT—bone cancer	1.61e-05	0.000295	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—GRM1—bone cancer	1.6e-05	0.000293	CbGpPWpGaD
Lapatinib—ERBB4—Innate Immune System—EGFR—bone cancer	1.59e-05	0.000291	CbGpPWpGaD
Lapatinib—ERBB4—Disease—KIT—bone cancer	1.59e-05	0.00029	CbGpPWpGaD
Lapatinib—EGFR—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	1.58e-05	0.00029	CbGpPWpGaD
Lapatinib—EGFR—Signaling by GPCR—IL3—bone cancer	1.58e-05	0.00029	CbGpPWpGaD
Lapatinib—EGFR—Disease—DHFR—bone cancer	1.57e-05	0.000288	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—IGF1R—bone cancer	1.55e-05	0.000285	CbGpPWpGaD
Lapatinib—ERBB2—Adaptive Immune System—EGFR—bone cancer	1.55e-05	0.000283	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—IGF1R—bone cancer	1.53e-05	0.00028	CbGpPWpGaD
Lapatinib—EGFR—Axon guidance—MMP9—bone cancer	1.53e-05	0.00028	CbGpPWpGaD
Lapatinib—ERBB4—Adaptive Immune System—EGFR—bone cancer	1.52e-05	0.000279	CbGpPWpGaD
Lapatinib—ERBB2—Disease—BRAF—bone cancer	1.51e-05	0.000277	CbGpPWpGaD
Lapatinib—ERBB4—Disease—BRAF—bone cancer	1.49e-05	0.000273	CbGpPWpGaD
Lapatinib—EGFR—Immune System—ATF1—bone cancer	1.48e-05	0.000271	CbGpPWpGaD
Lapatinib—EGFR—Developmental Biology—MMP2—bone cancer	1.45e-05	0.000266	CbGpPWpGaD
Lapatinib—EGFR—Innate Immune System—KIT—bone cancer	1.45e-05	0.000265	CbGpPWpGaD
Lapatinib—EGFR—Immune System—IL3—bone cancer	1.44e-05	0.000265	CbGpPWpGaD
Lapatinib—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	1.39e-05	0.000255	CbGpPWpGaD
Lapatinib—EGFR—Adaptive Immune System—KIT—bone cancer	1.39e-05	0.000255	CbGpPWpGaD
Lapatinib—ERBB2—Immune System—MDM2—bone cancer	1.37e-05	0.000251	CbGpPWpGaD
Lapatinib—ERBB4—Immune System—MDM2—bone cancer	1.35e-05	0.000248	CbGpPWpGaD
Lapatinib—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	1.34e-05	0.000246	CbGpPWpGaD
Lapatinib—ERBB2—Disease—MDM2—bone cancer	1.27e-05	0.000232	CbGpPWpGaD
Lapatinib—ERBB4—Disease—MDM2—bone cancer	1.25e-05	0.000229	CbGpPWpGaD
Lapatinib—ERBB2—Disease—PTGS2—bone cancer	1.22e-05	0.000224	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—NDUFA12—bone cancer	1.22e-05	0.000223	CbGpPWpGaD
Lapatinib—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	1.21e-05	0.000222	CbGpPWpGaD
Lapatinib—ERBB4—Disease—PTGS2—bone cancer	1.2e-05	0.00022	CbGpPWpGaD
Lapatinib—ERBB2—Immune System—JUN—bone cancer	1.19e-05	0.000219	CbGpPWpGaD
Lapatinib—ERBB4—Immune System—JUN—bone cancer	1.18e-05	0.000215	CbGpPWpGaD
Lapatinib—EGFR—Disease—TGFBR2—bone cancer	1.14e-05	0.000209	CbGpPWpGaD
Lapatinib—EGFR—Innate Immune System—MDM2—bone cancer	1.14e-05	0.000209	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—KIT—bone cancer	1.13e-05	0.000206	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—SMO—bone cancer	1.13e-05	0.000206	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—KIT—bone cancer	1.11e-05	0.000203	CbGpPWpGaD
Lapatinib—EGFR—Adaptive Immune System—MDM2—bone cancer	1.09e-05	0.0002	CbGpPWpGaD
Lapatinib—EGFR—Developmental Biology—MMP9—bone cancer	1.09e-05	0.0002	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—BRAF—bone cancer	1.06e-05	0.000194	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—BRAF—bone cancer	1.04e-05	0.000191	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—GNA11—bone cancer	1.03e-05	0.000189	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—NT5C3A—bone cancer	1.01e-05	0.000185	CbGpPWpGaD
Lapatinib—EGFR—Innate Immune System—JUN—bone cancer	9.91e-06	0.000181	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—ATF1—bone cancer	9.58e-06	0.000175	CbGpPWpGaD
Lapatinib—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	9.52e-06	0.000174	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—ENO2—bone cancer	9.51e-06	0.000174	CbGpPWpGaD
Lapatinib—ERBB2—Immune System—EGFR—bone cancer	9.39e-06	0.000172	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—IL3—bone cancer	9.34e-06	0.000171	CbGpPWpGaD
Lapatinib—ERBB4—Immune System—EGFR—bone cancer	9.25e-06	0.000169	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—MDM2—bone cancer	8.88e-06	0.000163	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—DHFR—bone cancer	8.82e-06	0.000161	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—MDM2—bone cancer	8.75e-06	0.00016	CbGpPWpGaD
Lapatinib—ERBB2—Disease—EGFR—bone cancer	8.67e-06	0.000159	CbGpPWpGaD
Lapatinib—ERBB4—Disease—EGFR—bone cancer	8.54e-06	0.000156	CbGpPWpGaD
Lapatinib—EGFR—Immune System—KIT—bone cancer	8.43e-06	0.000154	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—GNA11—bone cancer	8.24e-06	0.000151	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—ENO2—bone cancer	8.23e-06	0.000151	CbGpPWpGaD
Lapatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	8e-06	0.000146	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—TGFBR2—bone cancer	7.99e-06	0.000146	CbGpPWpGaD
Lapatinib—EGFR—Disease—KIT—bone cancer	7.78e-06	0.000143	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—JUN—bone cancer	7.72e-06	0.000141	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—DHFR—bone cancer	7.64e-06	0.00014	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—JUN—bone cancer	7.6e-06	0.000139	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—IGF1R—bone cancer	7.52e-06	0.000138	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—MMP9—bone cancer	7.51e-06	0.000138	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—CYP3A4—bone cancer	7.47e-06	0.000137	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—MMP9—bone cancer	7.4e-06	0.000135	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—ENO2—bone cancer	7.35e-06	0.000135	CbGpPWpGaD
Lapatinib—EGFR—Disease—BRAF—bone cancer	7.32e-06	0.000134	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—ENO2—bone cancer	7.17e-06	0.000131	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—GNA11—bone cancer	7.14e-06	0.000131	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—DHFR—bone cancer	6.82e-06	0.000125	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—DHFR—bone cancer	6.65e-06	0.000122	CbGpPWpGaD
Lapatinib—EGFR—Immune System—MDM2—bone cancer	6.64e-06	0.000122	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—CYP3A4—bone cancer	6.47e-06	0.000118	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	6.44e-06	0.000118	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—GSTP1—bone cancer	6.39e-06	0.000117	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—GNA11—bone cancer	6.37e-06	0.000117	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—GNA11—bone cancer	6.22e-06	0.000114	CbGpPWpGaD
Lapatinib—EGFR—Disease—MDM2—bone cancer	6.13e-06	0.000112	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—EGFR—bone cancer	6.07e-06	0.000111	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—EGFR—bone cancer	5.98e-06	0.000109	CbGpPWpGaD
Lapatinib—EGFR—Disease—PTGS2—bone cancer	5.91e-06	0.000108	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—CYP3A4—bone cancer	5.78e-06	0.000106	CbGpPWpGaD
Lapatinib—EGFR—Immune System—JUN—bone cancer	5.77e-06	0.000106	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	5.75e-06	0.000105	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—CYP3A4—bone cancer	5.64e-06	0.000103	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—GSTP1—bone cancer	5.54e-06	0.000101	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—KIT—bone cancer	5.45e-06	9.98e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—BRAF—bone cancer	5.12e-06	9.38e-05	CbGpPWpGaD
Lapatinib—ERBB2—Signaling Pathways—TP53—bone cancer	5.1e-06	9.33e-05	CbGpPWpGaD
Lapatinib—ERBB4—Signaling Pathways—TP53—bone cancer	5.02e-06	9.19e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—GSTP1—bone cancer	4.94e-06	9.05e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—GSTP1—bone cancer	4.82e-06	8.83e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—ENO2—bone cancer	4.42e-06	8.09e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—MDM2—bone cancer	4.29e-06	7.86e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—DHFR—bone cancer	4.1e-06	7.51e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—GNA11—bone cancer	3.83e-06	7.02e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—JUN—bone cancer	3.73e-06	6.83e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—MMP9—bone cancer	3.63e-06	6.65e-05	CbGpPWpGaD
Lapatinib—CYP3A5—Metabolism—PTGS2—bone cancer	3.31e-06	6.06e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—GSTP1—bone cancer	2.97e-06	5.44e-05	CbGpPWpGaD
Lapatinib—CYP2C8—Metabolism—PTGS2—bone cancer	2.87e-06	5.25e-05	CbGpPWpGaD
Lapatinib—CYP2C19—Metabolism—PTGS2—bone cancer	2.56e-06	4.69e-05	CbGpPWpGaD
Lapatinib—ABCB1—Metabolism—PTGS2—bone cancer	2.5e-06	4.57e-05	CbGpPWpGaD
Lapatinib—EGFR—Signaling Pathways—TP53—bone cancer	2.46e-06	4.51e-05	CbGpPWpGaD
Lapatinib—CYP3A4—Metabolism—PTGS2—bone cancer	1.54e-06	2.82e-05	CbGpPWpGaD
